Division of Organogenesis and Regeneration, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
Cancer Sci. 2018 Nov;109(11):3543-3553. doi: 10.1111/cas.13798. Epub 2018 Oct 15.
Hepatocellular carcinoma (HCC) accounts for a large proportion of liver cancer cases and has an extremely poor prognosis. Therefore, novel innovative therapies for HCC are strongly desired. As gene therapy tools for HCC, 2 hepatic transcription factors (TF), HNF4A and HNF1A, have been used to suppress proliferation and to extinguish cancer-specific characteristics of target cells. However, our present data demonstrated that single transduction of HNF4A or HNF1A had only a limited effect on suppression of HCC cell proliferation. Thus, in this study, we examined whether combinations of TF could show more effective antitumor activity, and found that combinatorial transduction of 3 hepatic TF, HNF4A, HNF1A and FOXA3, suppressed HCC cell proliferation more stably than single transduction of these TF. The combinatorial transduction also suppressed cancer-specific phenotypes, such as anchorage-independent growth in culture and tumorigenicity after transplantation into mice. HCC cell lines transduced with the 3 TF did not recover their proliferative property after withdrawal of anticancer drugs, indicating that combinatorial expression of the 3 TF suppressed the growth of all cell subtypes within the HCC cell lines, including cancer stem-like cells. Transcriptome analyses revealed that the expression levels of a specific gene set involved in cell proliferation were only decreased in HCC cells overexpressing all 3 TF. Moreover, combined transduction of the 3 TF could facilitate hepatic differentiation of HCC cell lines. Our strategy for inducing stable inhibition and functional differentiation of tumor cells using a defined set of TF will become an effective therapeutic strategy for various types of cancers.
肝细胞癌 (HCC) 占肝癌病例的很大比例,预后极差。因此,强烈需要针对 HCC 的新型创新疗法。作为 HCC 的基因治疗工具,2 种肝转录因子 (TF),HNF4A 和 HNF1A,已被用于抑制增殖并消除靶细胞的癌特异性特征。然而,我们目前的数据表明,单一转导 HNF4A 或 HNF1A 对抑制 HCC 细胞增殖的效果有限。因此,在这项研究中,我们研究了 TF 的组合是否可以显示出更有效的抗肿瘤活性,并发现 3 种肝 TF(HNF4A、HNF1A 和 FOXA3)的组合转导比单独转导这些 TF 更能稳定地抑制 HCC 细胞增殖。组合转导还抑制了特定的癌症表型,如培养中的非依赖性生长和移植到小鼠后肿瘤发生。用 3 种 TF 转导的 HCC 细胞系在撤回抗癌药物后并未恢复其增殖特性,这表明 3 种 TF 的组合表达抑制了 HCC 细胞系中所有细胞亚型的生长,包括癌症干细胞样细胞。转录组分析显示,参与细胞增殖的特定基因集的表达水平仅在过表达所有 3 种 TF 的 HCC 细胞中降低。此外,3 种 TF 的联合转导可以促进 HCC 细胞系的肝分化。我们使用一组定义的 TF 诱导肿瘤细胞稳定抑制和功能分化的策略将成为各种类型癌症的有效治疗策略。